Hot Seat Discussion on GLP-1 Receptor Agonists ...Your Questions Answered

Release date: December 20, 2011
Expiration date: December 20, 2012

This activity and the live symposium on which it is based were supported by an educational grant from Novo Nordisk, Inc. The live symposium, “Hot Seat Discussion on GLP-1 Receptor Agonists…Your Questions Answered,” which was presented Saturday, June 4, 2011, at The Endocrine Society’s 93rd Annual Meeting and Expo (ENDO 2011) in Boston, Massachusetts, was sponsored by The Endocrine Society and developed by the Institute for Medical and Nursing Education, Inc. (IMNE).

Activity Overview
Recent clinical trials have demonstrated the therapeutic efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) at different stages of diabetes progression, and exploratory studies suggest the potential for therapeutic uses other than glycemic control in patients with type 2 diabetes mellitus (T2DM). This continuing medical education (CME/CE) symposium will focus on hot topics arising from the most current information relevant to GLP-1 RAs.

Activity Format
This activity will include an introductory segment followed by 8 “hot topic” discussions consisting of of comparative answer polling questions; a short written excerpt of relevant, corresponding clinical data; and audio clips of the faculty roundtable discussion derived from questions received during the live activity.

Faculty
Jack Leahy, MD – Program Director
Professor of Medicine
Chief, Division of Endocrinology, Diabetes and Metabolism
The University of Vermont
Colchester, Vermont

Lawrence Blonde, MD, FACP, FACE
Director, Ochsner Diabetes Clinical Research Unit
Department of Diabetes, Endocrinology and Metabolism
Associate Internal Medicine Residency Program Director
Ochsner Medical Center
New Orleans, Louisiana

Alan J Garber, MD, PhD, FACE
Professor
Departments of Medicine,
Biochemistry and Molecular Biology,
Molecular and Cellular Biology
Baylor College of Medicine
Houston, Texas

Robert E Ratner, MD, FACP, FACE
Professor of Medicine
Georgetown University School of Medicine
Washington, DC
MedStar Health Research Institute
Hyattsville, Maryland

Intended Audience
This CME/CE activity should be of substantial interest to endocrinologists and other healthcare providers who treat patients with T2DM.

Educational Objectives
Upon completion of this educational activity, participants will be able to:

• Evaluate recent data on the efficacy and tolerability of GLP-1 RAs, including data from head-to-head trials
• Cite recent safety data for GLP-1 RAs, including cardiovascular (CV) safety, renal safety, pancreatitis risk, and thyroid tumor risk
• Incorporate into practice recent data regarding the optimal use of GLP-1 RAs, including uses at different stages of T2D progression
• Discuss nonglycemic effects of GLP-1 RAs, including their impact on weight and CV risk factors
• Describe recent data relevant to potential future uses for GLP-1 RAs other than glycemic control in T2D

CME/CE Accreditation and Designation Statements

Physicians
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  

The Endocrine Society has achieved Accreditation with Commendation.  

The Endocrine Society designates this enduring activity for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
The Institute for Medical and Nursing Education, Inc (IMNE) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC’s) Committee on Accreditation.
IMNE designates this educational activity for 2.25 contact hours (0.25 CEUs). Accreditation by the ANCC’s Committee on Accreditation refers to recognition of educational activities and does not imply approval or endorsement of any product.

Diabetes Educators
ANCC-accredited providers have been approved by the National Certification Board for Diabetes Educators (NCBDE) as providers of continuing education (CE). Individuals seeking recertification from the NCBDE can use the CE contact hours received through participation in this activity.

Statement of Independence
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of The Endocrine Society’s Special Programs Committee (SPC). The commercial supporters of this activity have no influence over the selection of the faculty or specific presentations. 

Disclaimer
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of The Endocrine Society or IMNE.

The faculty, committee members, and staff involved in planning this CME/CE activity are required to disclose to learners any relevant financial relationship(s) that have occurred within the last 12 months with any commercial interest(s) whose products or services are discussed in the CME content. Such relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (eg, stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent faculty with relevant financial relationships from planning or delivering content but rather to provide learners with information that allows them to make their own judgments. It remains for learners to determine whether financial interests or relationships may influence the educational activity with regard to exposition or conclusion.

The Endocrine Society and IMNE have reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The following faculty reported relevant financial relationships:
Jack Leahy, MD
Advisory Board Member: Merck & Co, Inc, and Novo Nordisk Inc
Consultant and Speaker: sanofi-aventis
Research Grant and Salary Recipient: Takeda Pharmaceuticals North America, Inc.

Lawrence Blonde, MD, FACP, FACE
Consultant: Amylin Pharmaceuticals, Inc; AstraZeneca Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo Co, Ltd; GlaxoSmithKline; Halozyme Therapeutics; Johnson & Johnson; MannKind Corporation; Merck & Co, Inc; Novo Nordisk Inc; Orexigen Therapeutics, Inc; Roche Pharmaceuticals; sanofi-aventis; Santarus, Inc; VeroScience, LLC
Research Grant Recipient: Boehringer Ingelheim; Eli Lilly and Company; Johnson & Johnson; Novo Nordisk Inc; Roche Pharmaceuticals; sanofi-aventis
Speaker: AstraZeneca Pharmaceuticals; Boehringer Ingelheim; Bristol-Myers Squibb Company; Daiichi Sankyo Co, Ltd; Merck & Co, Inc; Novo Nordisk Inc; Santarus, Inc; VeroScience, LLC

Alan J Garber, MD, PhD, FACE
Advisory Board Member and Consultant: Daiichi Sankyo Co, Ltd; GlaxoSmithKline; Merck & Co, Inc; Novo Nordisk Inc; Roche Pharmaceuticals
Speaker: Daiichi Sankyo Co, Ltd; GlaxoSmithKline; Merck & Co, Inc; Novo Nordisk Inc

Robert E Ratner, MD, FACP, FACE
Advisory Board Member: Amylin Pharmaceuticals, Inc; AstraZeneca Pharmaceuticals; Novo Nordisk Inc; sanofi-aventis;
Research Grant Recipient: Bayhill Therapeutics; Genentech, Inc; GlaxoSmithKline; Integrium, LLC; Novo Nordisk Inc; sanofi-aventis; VeraLight, Inc
Stock Ownership: Abbott Laboratories; Johnson & Johnson; Merck & Co, Inc.

The following committee member(s) who planned and/or reviewed content for this activity reported relevant financial relationships:

Steven R Smith, MD
Advisory board member: Amylin Pharmaceuticals; Arena Pharmaceuticals
Consultant: Amylin Pharmaceuticals; Arena Pharmaceuticals; AstraZeneca; Novartis.

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

The IMNE staff associated with the development of content for this activity reported no relevant financial relationships.

The medical editors for this program, Kim McFarland, PhD, and Angela McIntosh, PhD, reported no relevant financial relationships.

Policy on Unlabeled/Off-Label Use
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation.

Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the US Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.

Privacy & Confidentiality Statement
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Novo Nordisk Inc.